参考文献/References:
[1]Li Z,Lin L,Wu H,et al. Global,regional,and national death,and disability-adjusted life-years(DALYs) for cardiovascular disease in 2017 and trends and risk analysis from 1990 to 2017 using the global burden of disease study and implications for prevention[J]. Front Public Health,2021,29(9):559751.
[2]Grundy SM,Stone NJ,Bailey AL,et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol:A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines[J]. Circulation,2019,139(25):e1082-e1143.
[3]Rhee EJ,Kim HC,Kim JH,et al. 2018 Guidelines for the management of dyslipidemia[J]. Korean J Intern Med,2019,34(4):723-771.
[4]Cannon CP,Blazing MA,Giugliano RP,et al. Ezetimibe added to statin therapy after acute coronary syndromes[J]. N Engl J Med,2015,372(25):2387-2397.
[5]Mach F,Baigent C,Catapano AL,et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias:lipid modification to reduce cardiovascular risk[J]. Eur Heart J,2020,41(1):111-188.
[6]Libby P,Buring JE,Badimon L,et al. Atherosclerosis[J]. Nat Rev Dis Primers,2019,5(1):56.
[7]Borén J,Williams KJ. The central role of arterial retention of cholesterol-rich apolipoprotein-B-containing lipoproteins in the pathogenesis of atherosclerosis:a triumph of simplicity[J]. Curr Opin Lipidol ,2016,27(5):473-483.
[8]Contois JH,Warnick GR,Sniderman AD. Reliability of low-density lipoprotein cholesterol,non-high-density lipoprotein cholesterol,and apolipoprotein B measurement[J]. J Clin Lipidol ,2011,5(4):264-272.
[9]Castelli WP,Garrison RJ,Wilson PW,et al. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study[J]. JAMA,1986,256(20):2835-2838.
[10]Subramanian S. Approach to the patient with moderate hypertriglyceridemia[J]. J Clin Endocrinol Metab,2022,107(6):1686-1697.
[11]Patel AP,Wang M,Pirruccello JP,et al. Lp(a) [Lipoprotein(a)] concentrations and incident atherosclerotic cardiovascular disease:new insights from a large national biobank[J]. Arterioscler Thromb Vasc Biol,2021,41(1):465-474.
[12] Expert Panel on Detection,Evaluation,and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program(NCEP) expert panel on detection,evaluation,and treatment of high blood cholesterol in adults(Adult Treatment Panel Ⅲ)[J]. JAMA,2001,285(19):2486-2497.
[13]Sniderman AD,Thanassoulis G,Glavinovic T,et al. Apolipoprotein B particles and cardiovascular disease:a narrative review[J]. JAMA Cardiol,2019,4(12):1287-1295.
[14] Olofsson SO,Borèn J. Apolipoprotein B:a clinically important apolipoprotein which assembles atherogenic lipoproteins and promotes the development of atherosclerosis[J]. J Intern Med,2005,258(5):395-410.
[15]Sacks D,Baxter B,Campbell BCV,et al. Multisociety consensus quality improvement revised consensus statement for endovascular therapy of acute ischemic stroke[J]. Int J Stroke,2018,13(6):612-632.
[16]Sabatine MS,Giugliano RP,Keech AC,et al. Evolocumab and clinical outcomes in patients with cardiovascular disease[J]. N Engl J Med,2017,376(18):1713-1722.
[17]Schwartz GG,Steg PG,Szarek M,et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome[J]. N Engl J Med ,2018,379(22):2097-2107.
[18]Maki KC. The ODYSSEY outcomes trial:clinical implications?and exploration of the limits of what?can be achieved through lipid lowering[J]. J Clin Lipidol,2018,12(5):1102-1105.
[19]Ray KK,Colhoun HM,Szarek M,et al. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes:a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial[J]. Lancet Diabetes Endocrinol ,2019,7(8):618-628.
[20]Egan BM,Sutherland SE,Childers WF,et al. Comparative impact of implementing the 2013 or 2014 cholesterol guideline on vascular events in a quality improvement network[J]. Ther Adv Cardiovasc Dis,2016,10(2):56-66.
[21]Jiang R,Schulze MB,Li T,et al. Non-HDL cholesterol and apolipoprotein B predict cardiovascular disease events among men with type 2 diabetes[J]. Diabetes Care,2004,27(8):1991-1997.
[22]Langlois MR,Sniderman AD. Non-HDL cholesterol or apoB:which to prefer as a target for the prevention of atherosclerotic cardiovascular disease?[J]. Curr Cardiol Rep,2020,22(8):67.
[23]Zhang M,Deng Q,Wang L,et al. Prevalence of dyslipidemia and achievement of low-density lipoprotein cholesterol targets in Chinese adults:a nationally representative survey of 163,641 adults[J]. Int J Cardiol,2018,260:196-203.
[24]Langlois MR,Descamps OS,van der Laarse A,et al. Clinical impact of direct HDLc and LDLc method bias in hypertriglyceridemia. A simulation study of the EAS-EFLM collaborative project group[J]. Atherosclerosis,2014,233(1):83-90.
[25]Langlois MR,Nordestgaard BG,Langsted A,et al. Quantifying atherogenic lipoproteins for lipid-lowering strategies:consensus-based recommendations from EAS and EFLM[J]. Clin Chem Lab Med,2020,58(4):496-517.
[26]Einarson TR,Acs A,Ludwig C,et al. Economic burden of cardiovascular disease in type 2 diabetes:a systematic review[J]. Value Health,2018,21(7):881-890.
[27]Fonseca L,Paredes S,Ramos H,et al. Apolipoprotein B and non-high-density lipoprotein cholesterol reveal a high atherogenicity in individuals with type 2 diabetes and controlled low-density lipoprotein-cholesterol[J]. Lipids Health Dis,2020,19(1):127.
[28]Martin SS,Qasim AN,Mehta NN,et al. Apolipoprotein B but not LDL cholesterol is associated with coronary artery calcification in type 2 diabetic whites[J]. Diabetes,2009,58(8):1887-1892.
[29]Razavi AC,Bazzano LA,He J,et al. Discordantly normal ApoB relative to elevated LDL-C in persons with metabolic disorders:a marker of atherogenic heterogeneity[J]. Am J Prev Cardiol,2021,7:100190.
[30]Saklayen MG. The global epidemic of the metabolic syndrome[J]. Curr Hypertens Rep,2018,20(2):12.
[31]Barbalho SM,Tofano RJ,de Oliveira MB,et al. HDL-C and non-HDL-C levels are associated with anthropometric and biochemical parameters[J]. J Vasc Bras,2019,18:e20180109.
[32]Elhadad MA,Wilson R,Zaghlool SB,et al. Metabolic syndrome and the plasma proteome:from association to causation[J]. Cardiovasc Diabetol,2021,20(1):111.
[33]Robinson JG,Wang S,Smith BJ,et al. Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk[J]. J Am Coll Cardiol,2009,53(4):316-322.
[34]Khan SU,Khan MU,Valavoor S,et al. Association of lowering apolipoprotein B with cardiovascular outcomes across various lipid-lowering therapies:systematic review and meta-analysis of trials[J]. Eur J Prev Cardiol ,2020,27(12):1255-1268.
[35]Sniderman AD,Williams K,Contois JH,et al. A meta-analysis of low-density lipoprotein cholesterol,non-high-density lipoprotein cholesterol,and apolipoprotein B as markers of cardiovascular risk[J]. Circ Cardiovasc Qual Outcomes,2011,4(3):337-345.
[36]Sniderman A,Langlois M,Cobbaert C. Update on apolipoprotein B[J]. Curr Opin Lipidol ,2021,32(4):226-230.
[37]Langlois MR. Investigations on the clinical utility of apolipoprotein B measurement:a research priority[J]. Eur J Prev Cardiol,2020,27(12):1252-1254.
[38]Nurmohamed NS,Navar AM,Kastelein JJP. New and emerging therapies for reduction of LDL-cholesterol and apolipoprotein B:JACC focus seminar 1/4[J]. J Am Coll Cardiol,2021,77(12):1564-1575.
[39]Toth PP,Jones SR,Monsalvo ML,et al. Effect of evolocumab on non-high-density lipoprotein cholesterol,apolipoprotein B,and lipoprotein(a):a pooled analysis of phase 2 and phase 3 studies[J]. J Am Heart Assoc,2020,9(5):e014129.
[40]Carr SS,Hooper AJ,Sullivan DR,et al. Non-HDL-cholesterol and apolipoprotein B compared with LDL-cholesterol in atherosclerotic cardiovascular disease risk assessment[J]. Pathology,2019,51(2):148-154.
相似文献/References:
[1]史云聪 郭艺芳.2型糖尿病和动脉粥样硬化性心血管疾病的关系[J].心血管病学进展,2020,(5):485.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.011]
SHI Yuncong,GUO Yifang.Relationship Between Type 2 Diabetes Mellitus and Atherosclerotic Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2020,(9):485.[doi:10.16806/j.cnki.issn.1004-3934.2020.05.011]
[2]李艳茹,白世茹,李如意,等.PCSK9抑制剂在血脂代谢中的研究进展[J].心血管病学进展,2020,(7):729.[doi:10.16806/j.cnki.issn.1004-3934.2020.07.014]
LI Yanru,BAI Shiru,LI Ruyi,et al.PCSK9 Inhibitors in Lipid Metabolism[J].Advances in Cardiovascular Diseases,2020,(9):729.[doi:10.16806/j.cnki.issn.1004-3934.2020.07.014]
[3]马晓磊 朱国斌.Wnt信号与动脉粥样硬化性心血管疾病研究进展[J].心血管病学进展,2020,(8):855.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.018]
MA Xiaolei,ZHU Guobin.Wnt Signaling and Atherosclerotic Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2020,(9):855.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.018]
[4]黄毕.慢性肾脏病合并动脉粥样硬化性心血管疾病的调脂治疗进展[J].心血管病学进展,2020,(10):1065.[doi:10.16806/j.cnki.issn.1004-3934.2020.10.016]
HUANG Bi.Lipid Management in Patients with Chronic Kidney Disease and Arteriosclerotic Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2020,(9):1065.[doi:10.16806/j.cnki.issn.1004-3934.2020.10.016]
[5]姚雅洁 蔡恒.PCSK9抑制剂Evolocumab动脉粥样硬化性心血管疾病的研究进展[J].心血管病学进展,2020,(12):1285.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.015]
YAO Yajie,CAI Heng.PCSK9 Inhibitor Evolocumab and ASCVD[J].Advances in Cardiovascular Diseases,2020,(9):1285.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.015]
[6]于洋杰 谢坤 高秀芳 施海明 李勇.非高密度脂蛋白胆固醇可以替代低密度脂蛋白胆固醇吗？[J].心血管病学进展,2021,(1):12.[doi:10.16806/j.cnki.issn.1004-3934.2021.01.000]
YU Yangjie,XIE Kun,GAO Xiufang,et al.Can LDL-C be Replaced by non-HDL-C[J].Advances in Cardiovascular Diseases,2021,(9):12.[doi:10.16806/j.cnki.issn.1004-3934.2021.01.000]
[7]曹岩 颜培实.残余胆固醇与动脉粥样硬化性心血管疾病[J].心血管病学进展,2021,(10):920.[doi:10.16806/j.cnki.issn.1004-3934.2021.10.014]
CAO Yan,YAN Peishi.Remnant Cholesterol And Atherosclerotic?ardiovascular Disease[J].Advances in Cardiovascular Diseases,2021,(9):920.[doi:10.16806/j.cnki.issn.1004-3934.2021.10.014]
[8]蔡薇 杨堰焯 刘昊凌.甘油三酯葡萄糖乘积指数与糖尿病血管病变的研究进展[J].心血管病学进展,2022,(3):245.[doi:10.16806/j.cnki.issn.1004-3934.2022.03.000]
CAI Wei,YANG Yanzhuo,LIU Haoling.Triglyceride-Glucose Index and Diabetic Vascular Disease[J].Advances in Cardiovascular Diseases,2022,(9):245.[doi:10.16806/j.cnki.issn.1004-3934.2022.03.000]
[9]陈林滔 田清平 刘梅林.残余胆固醇预测动脉粥样硬化性心血管疾病的研究进展[J].心血管病学进展,2022,(6):492.[doi:10.16806/j.cnki.issn.1004-3934.2022.06.004]
CHEN Lintao,TIAN Qingping,LIU Meilin.Remnant Cholesterol in Predicting Atherosclerotic Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2022,(9):492.[doi:10.16806/j.cnki.issn.1004-3934.2022.06.004]
[10].胆固醇酯转移蛋白抑制剂在动脉粥样硬化性心血管疾病治疗中的研究进展[J].心血管病学进展,2022,(7):600.[doi:10.16806/j.cnki.issn.1004-3934.2022.07.000]
ZHU Jie,GAO Fen,XUE Shuanqin,et al.Treatment of Atherosclerotic Cardiovascular Diseases with Cholesteryl Ester Transfer Protein Inhibitor[J].Advances in Cardiovascular Diseases,2022,(9):600.[doi:10.16806/j.cnki.issn.1004-3934.2022.07.000]